Aims/hypothesis
Islet cell death is a key initiating and perpetuating event in type 1 diabetes and involves both immune-mediated and endogenous
mechanisms. The epithelial pantetheinase vanin-1 is proinflammatory and cytoprotective via cysteamine release in some tissues.
We investigated the impact of a vanin-1 deficiency on islet death and type 1 diabetes incidence.
Methods
Vanin-1-deficient mice were produced and tested in drug-induced and autoimmune diabetes models. The contribution of vanin-1
to islet survival versus immune responses was evaluated using lymphocyte transfer and islet culture experiments.
Results
The vanin-1/cysteamine pathway contributes to the protection of islet beta cells from streptozotocin-induced death in vitro
and in vivo. Furthermore, vanin-1-deficient NOD mice showed a significant aggravation of diabetes, which depended upon loss
of vanin-1 expression by host tissues. This increased islet fragility was accompanied by greater CD4+ insulitis without impairment
of regulatory cells. Addition of cystamine, the product of pantetheinase activity, protected islets in vitro and compensated
for vanin-1 deficiency in vivo.
Conclusions/interpretation
This study unravels a major cytoprotective role of cysteamine for islet cells and suggests that modulation of pantetheinase
activity may offer alternative strategies to maintain islet cell homeostasis.
Keywords Cystamine - Cytoprotection - Islet beta cells - Pantetheinase - Type 1 diabetes